Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

408

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

March 31, 2029

Conditions

Pancreatic Cancer

Interventions

DRUG

Liposomal Irinotecan

Liposomal Irinotecan：i.v. infusion

DRUG

Oxaliplatin

Oxaliplatin;：i.v. infusion

DRUG

S-1

S-1: Oral

DRUG

Gemcitabine

Gemcitabine: i.v. infusion

DRUG

Capecitabine

Capecitabine: Oral